Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 9/20 | 0.40 |
| ▸ | CA12 | O43570 | 9/20 | 0.39 |
| ▸ | CA1 | P00915 | 9/20 | 0.39 |
| ▸ | CA2 | P00918 | 9/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | CA4 | P22748 | 4/20 | 0.39 |
| ▸ | CA5A | P35218 | 4/20 | 0.39 |
| ▸ | CA7 | P43166 | 4/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10228169 | 1.00 | TSHR (0.49) | TSHRPTPN1SLC5A2CA12CA1 | |
| SCHEMBL29657483 | 1.00 | TSHR (0.49) | TSHRPTPN1SLC5A2CA12CA1 | |
| SCHEMBL16730393 | 1.00 | TSHR (0.49) | TSHRPTPN1SLC5A2CA12CA1 | |
| SCHEMBL16730398 | 1.00 | TSHR (0.49) | TSHRPTPN1SLC5A2CA12CA1 | |
| SCHEMBL15030983 | 1.00 | TSHR (0.49) | TSHRPTPN1SLC5A2CA12CA1 | |
| SCHEMBL1670038 | 1.00 | TSHR (0.49) | TSHRPTPN1SLC5A2CA12CA1 | |
| SCHEMBL18511218 | 0.94 | TSHR (0.41) | TSHRSLC5A2CA12CA1CA2 | |
| SCHEMBL10328151 | 0.94 | TSHR (0.41) | TSHRSLC5A2CA12CA1CA2 | |
| SCHEMBL18511214 | 0.94 | TSHR (0.41) | TSHRSLC5A2CA12CA1CA2 | |
| SCHEMBL16730399 | 0.86 | TSHR (0.53) | TSHRPTPN1SLC5A2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8828951-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130017993-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | TSHR 4409/4885PTPN1 723/4885SLC5A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.